Zenas BioPharma, Inc.
NASDAQ:ZBIO · NASDAQ Global Select
+$0.64 today
Vol 2.13M · Avg 0.71M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ZBIO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$425.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-9.10, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.0M +100.0% | $5.0M -90.0% | $50.0M | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 -100.0% | $139.1M | $0 -100.0% | $61.7M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $10.0M +107.5% | -$134.1M -368.3% | $50.0M +181.1% | -$61.7M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 100.0% +2782.8pp | -2682.8% -2782.8pp | 100.0% | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $168.1M +20.8% | $139.1M +131.8% | $60.0M -4.2% | $62.7M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $53.3M +79.2% | $29.7M +73.8% | $17.1M +26.7% | $13.5M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $221.4M +644.2% | $29.7M -65.9% | $87.1M +500.6% | $14.5M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $56.0K -59.1% | $137.0K +21.2% | $113.0K +44.9% | $78.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$370.4M -136.8% | -$156.4M -478.6% | -$27.0M +64.0% | -$75.1M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | -3704.3% -575.9pp | -3128.4% -3074.4pp | -54.1% | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$211.4M -29.0% | -$163.9M -341.2% | -$37.1M +51.3% | -$76.2M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -2113.8% +1163.9pp | -3277.8% -3203.5pp | -74.3% | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $12.2M | $0 | $0 | $0 | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $7.3M | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$166.4M -2370.9% | $7.3M +2162.0% | $324.0K +100.8% | -$43.1M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$377.8M -141.3% | -$156.6M -325.2% | -$36.8M +69.1% | -$119.3M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -3778.2% -647.0pp | -3131.2% -3057.5pp | -73.6% | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | -$79.0K -118.4% | $429.0K +42.5% | $301.0K | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$377.7M -140.6% | -$157.0M -322.9% | -$37.1M +68.9% | -$119.3M | $5.0B | $4.9B | $4.8B |
| Net Margin | -3777.4% -637.6pp | -3139.8% -3065.5pp | -74.2% | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$8 -124.5% | -$4 -287.6% | -$1 +68.8% | -$3 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$8 -124.5% | -$4 -287.6% | -$1 +68.8% | -$3 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $44.7M +7.0% | $41.8M +9.1% | $38.3M +0.0% | $38.3M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $44.7M +7.0% | $41.8M +9.1% | $38.3M +0.0% | $38.3M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.82B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.37B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.71B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.70B
Novavax, Inc.
NASDAQ:NVAX
$1.52B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.28B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.17B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$886.63M
Upstream Bio, Inc.
NASDAQ:UPB
$344.48M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ZBIO generate?
Zenas BioPharma, Inc. (ZBIO) reported $10.00M of revenue in fiscal 2025.
Is ZBIO profitable?
Zenas BioPharma, Inc. (ZBIO) reported -$377,737,000.00 of net income, with a net margin of -3777.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.